Free Trial
NASDAQ:CRTX

Cortexyme (CRTX) Stock Price, News & Analysis

Cortexyme logo
$1.84 +0.07 (+3.95%)
(As of 11/20/2024 ET)

About Cortexyme Stock (NASDAQ:CRTX)

Key Stats

Today's Range
$1.77
$1.87
50-Day Range
$0.69
$1.95
52-Week Range
$1.78
$40.66
Volume
140,411 shs
Average Volume
620,672 shs
Market Capitalization
$55.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Stock News Headlines

Crism Thera Regulatory News
Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
See More Headlines

CRTX Stock Analysis - Frequently Asked Questions

Cortexyme's stock was trading at $1.05 at the beginning of the year. Since then, CRTX stock has increased by 75.2% and is now trading at $1.84.
View the best growth stocks for 2024 here
.

Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.05.

Cortexyme (CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cortexyme investors own include Alibaba Group (BABA), Enterprise Products Partners (EPD), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Meta Platforms (META) and AT&T (T).

Company Calendar

Last Earnings
8/09/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:CRTX
CUSIP
21924P10
Fax
N/A
Employees
55
Year Founded
2012

Profitability

Net Income
$-89,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.97 per share

Miscellaneous

Free Float
21,739,000
Market Cap
$55.48 million
Optionable
Not Optionable
Beta
1.40

Social Links

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CRTX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners